The University of Oxford and AstraZeneca PLC have released Phase I results from their COVID-19 vaccine, the early trial producing encouraging safety and efficacy signals, but a neutralizing antibody response that appears to be less strong than its rivals.
The study published in The Lancet of more than 1,000 healthy adult volunteers provides a solid base for the partners...





![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)
